Evaxion Biotech A/S (EVAX)
Evaxion announces business update and third quarter 2025 financial results
Johnson & Johnson (JNJ)
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
Plus Therapeutics Inc (PSTV)
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0
Silence Therapeutics, Plc. (SLNCF)
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Organon & Co. (OGN)
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
Catalyst Biosciences Inc. (CBIO)
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Collegium Pharmaceutical Inc (COLL)
Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance
Silence Therapeutics Plc (SLN)
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Lexicon Pharmaceuticals Inc. (LXRX)
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
Cybin Inc (CYBN)
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025